Online inquiry

IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11222MR)

This product GTTS-WQ11222MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets pcrV&psl gene. The antibody can be applied in P. Aeruginosa nosocomial pneumonia research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens; Humanized
RefSeq WP_003100789.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
UniProt ID O30527
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11222MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13835MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-1193
GTTS-WQ4861MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BTCT4465A
GTTS-WQ13057MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ11123MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MDX-1103
GTTS-WQ12993MR IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PEG sTNF-RI
GTTS-WQ9808MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA JS004
GTTS-WQ14145MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA aPCSK927
GTTS-WQ2572MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 479
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW